Tango Therapeutics, Inc.
TNGXUnited States
24 filed reports · 304 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
24 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,218 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 1,755 | Dec 2020 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 287 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 13, 2026 | 176 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 5, 2026 | 642 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 199 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 123 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 125 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 313 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 121 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 106 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 110 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 18, 2024 | 167 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 8, 2023 | 120 | Open |
Financial data
304 concepts · 3,973 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial302 concepts · 3,807 facts · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital share based compensation stock options requisite service period recognition32 · Mar 2020 to Jun 2026
- Net income loss32 · Mar 2020 to Jun 2026
- Other comprehensive income loss tax32 · Mar 2020 to Jun 2026
- Stockholders equity (US GAAP)32 · Mar 2020 to Jun 2026
- Cash and cash equivalents at carrying value31 · Jun 2020 to Jun 2026
- Common stock shares outstanding31 · Sep 2020 to Jun 2026
- Accounts payable current30 · Sep 2020 to Jun 2026
- Allocated share based compensation expense30 · Sep 2020 to Jun 2026
- Assets30 · Sep 2020 to Jun 2026
- Assets current30 · Sep 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations30 · Sep 2020 to Jun 2026
- Common stock par or stated value per share30 · Sep 2020 to Jun 2026
- Common stock shares authorized30 · Sep 2020 to Jun 2026
- Common stock shares issued30 · Sep 2020 to Jun 2026
- Common stock value30 · Sep 2020 to Jun 2026
- Comprehensive income net of tax30 · Sep 2020 to Jun 2026
- Depreciation30 · Sep 2020 to Jun 2026
- General and administrative expense (US GAAP)30 · Sep 2020 to Jun 2026
- Income tax expense benefit30 · Sep 2020 to Jun 2026
- Interest income expense net30 · Sep 2020 to Jun 2026
- Liabilities30 · Sep 2020 to Jun 2026
- Liabilities and stockholders equity30 · Sep 2020 to Jun 2026
- Liabilities current30 · Sep 2020 to Jun 2026
- Marketable securities unrealized gain loss30 · Sep 2020 to Jun 2026
Segment1 concepts · 126 facts · Dec 2022 to Jun 2026
- Research and development expense126 · Dec 2022 to Jun 2026
Product1 concepts · 40 facts · Sep 2020 to Dec 2025
- Revenue40 · Sep 2020 to Dec 2025
Segments
166 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments10 members · 126 facts
- Discovery Direct Program Expenses-RD14 · Dec 2022 to Jun 2026
- Facilities And Other Related Expenses-RD14 · Dec 2022 to Jun 2026
- Personnel- Related Expenses-RD14 · Dec 2022 to Jun 2026
- TNG260 Direct Program Expenses-RD14 · Dec 2022 to Jun 2026
- TNG908 Direct Program Expenses-RD14 · Dec 2022 to Jun 2026
- TNG456 Direct Program Expenses-RD13 · Dec 2023 to Jun 2026
- TNG961 Direct Program Expenses-RD13 · Dec 2023 to Jun 2026
- TNG348 Direct Program Expenses-RD12 · Dec 2022 to Dec 2025
- Vopimetostat Direct Program Expenses-RD11 · Dec 2023 to Jun 2026
- TNG462 Direct Program Expenses-RD7 · Dec 2022 to Jun 2025
Product or service2 members · 40 facts
- Collaboration Revenue25 · Sep 2020 to Dec 2025
- License Revenue15 · Sep 2020 to Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.